Document is current

Article History

Received: 1 May 2023

Accepted: 27 September 2023

First Online: 12 October 2023

Declarations

:

: The OPTIMISER (A Prospective Cohort Study to Describe the OPTIMal Management and Outcomes of PatIents PreSEnting with Acute MyocaRdial Infarction) Registry has been reviewed and approved by the Ethikkommission Nordwest- und Zentralschweiz (EKNZ) (project ID 2020–02559; Basel, Switzerland; 2021/01/22) All patients had given their consent to participate in the study. This consent was informed. We confirm that all methods were carried out in accordance with relevant guidelines and regulations (Declaration of Helsinki).

: The informed consent obtained from every individual, who has been enrolled in the OPTIMISER study, allows data collection and analysis, as well as publication of the analyzed data. Accordingly, all patients provided consent to publication of the data. Of note, all patients have been informed that their data will be de-identified (ananomyzed) and stored on a secured server.

: GMC, YZ, MM, TS, LS, VG, JPR report no conflicts of interest. AAT has received consulting and speaker fees from Abbott Vascular, Abiomed, SIS Medical and Vifor. MB has received consulting and speaker fees from Abbott Vascular, Abiomed, Amgen, Astra Zeneca, Bayer, Daichii Sankyo, Mundipharma and SIS Medical. FC has received consulting and speaker fees from Abiomed, Abbott Vascular and SIS Medical.